Abstract: A method of synthesizing aerogels and cross-linked aerogels in a single step and in a single pot without requiring any solvent exchange is described. Porous matrices are synthesized through a modification of hydrolysis condensation of alkoxides in which addition of water is minimized. The reaction occurs in an ethanol-water azeotrope mixture; the water in the azeotrope slowly hydrolyzes the alkoxide. Additionally, after gelation, the porous matrix is dried in supercritical ethanol rather than liquid CO2, which allows for elimination of solvent exchange steps. These modifications allow for the preparation of aerogel monoliths in any size in one step and in one pot and much faster than conventional procedures. In addition, the method provides for custom aerogel parts with large dimensions, as well as high volume fabrication of aerogels. The custom aerogel parts may be used in a variety of thermal insulation applications.

Abstract: A compound having the formula: wherein n, y, R1 and R2 are defined herein, and others, methods of making of and using, and compositions made thereby which have an antimicrobial resistance effect are described.

Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.

Abstract: Azolylacryloyl derivatives with hypoxic properties are provided. The compounds have a generic formula: and are suitable for treating sickle cell disease and hypoxia-underlying diseases, e.g. hemorrhagic and traumatic shock, cardiac arrest and cardiogenic shock, traumatic brain injury, cancer, stroke, myocardial infarction, myocardial ischemia, vaso-occlusive crisis, etc.

Abstract: Inhibitors that are anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as heart failure and autoimmune diseases.

Abstract: A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-?B-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.

Abstract: Compositions, methods and kits for treating victims of carbon monoxide and/or cyanide poisoning and/or nitric acid-induced vasoplagia are provided. The compositions comprise reduced forms of Vitamin B12 such as reduced hydroxocobalamin or reduced cobinamide, and typically comprise at least one reducing agent (e.g. ascorbic acid). The compositions are generally produced, stored and delivered under reducing, usually anaerobic, conditions in order to preserve the desired oxidation state when introduced into the blood stream of a recipient.

Abstract: A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

Abstract: The invention relates to endovascular medical implant devices, systems and methods that including a sensing device and a flow diverter device, which are effective to monitor intra-/post-operative hemodynamic properties in the location of a cerebral aneurysm and, hemodynamic alterations following placement of the system for treating ischemic diseases in carotid, coronary and peripheral arteries. The sensing device includes wireless, non-thrombogenic, highly stretchable, ultra-low profile flow sensors.

Abstract: An organ protectant solution which is intravenously administered includes at least one oncotic agent and optionally a high concentration of cell-impermeant molecules. Together, they promote transfer of water from cells to interstitium and into the capillaries, thereby preventing or reducing cell swelling, maintaining blood circulation and oxygenation of tissues, and extending the “Golden Hour” for traumatic and/or hemorrhagic shock patients. In addition, compositions comprising PEG-20k and methods of their use for preserving and/or reanimating harvested organs ex vivo for lengthy periods of time (e.g. at least about 8-24 hours) are also provided.

Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.

Abstract: Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.

Abstract: A portable electronic alcohol-testing device is provided that uses vaporization and sensitive pressure guages to approximate the alcohol content of a solution. The device may be used, for example, to determine the relative alcohol content of a mixed beverage.

Abstract: A compound is provided, having the formula (I), wherein Rs is a soft block polymer; wherein each T is independently a urethane or urea linkage; see formulae (A) and (B); wherein each RD is independently —CH3, —CH2CH3, —CH2CH2CH3, or —CH2CH2CH2CH3; wherein each R?D is independently —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, or —ORD; and wherein each p is independently 1, 2, or 3. Compositions containing the compound, and methods of making and using the compound are provided.

Abstract: Pharmaceutical compositions and methods for the treatment of DENND1A.V2 related disorders, such as PCOS, are provided. In particular, humanized and mouse monoclonal antibodies specific for DENND1A.V2 and methods for using the same are provided.

Abstract: The presently disclosed subject matter generally relates to genetic constructs and methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. In particular, the presently disclosed subject matter relates to tripartite cancer theranostic nucleic acid constructs that permit simultaneous cancer specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

Abstract: Methods and compositions for enhancing the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors are provided. Local regions of hypoxia are created within a tumor, or within a region containing a tumor, resulting in enhanced activation of hypoxia-activated bioreductive agents (e.g. tirapazamine) within the local region. The activated hypoxia-activated bioreductive agents kill tumor cells in the hypoxic region by catalyzing DNA stand breakage within the tumor cells. Because the activity is localized, side effects that typically occur as a result of systemic administration of bioreductive agents are reduced.

Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

Abstract: A compound having the formula: wherein n, y, R1 and R2 are defined herein, and others, methods of making of and using, and compositions made thereby which have an antimicrobial resistance effect are described.